CeriBell will announce Q3 2025 financial results on November 4, 2025, followed by a conference call.
Quiver AI Summary
CeriBell, Inc., a medical technology company focused on improving the diagnosis and management of serious neurological conditions, will announce its financial results for the third quarter of 2025 on November 4, 2025, after trading closes. A conference call to discuss the results will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day, with participation details provided for both domestic and international callers. CeriBell has developed the Ceribell System, a point-of-care electroencephalography platform that incorporates portable hardware and AI algorithms for rapid diagnosis and monitoring of neurological conditions, and is used in acute care settings like ICU and emergency rooms. The company is based in Sunnyvale, California, and additional information is available on their website.
Potential Positives
- Ceribell is positioned for growth by providing a novel, point-of-care EEG platform that addresses unmet needs in acute care settings.
- The upcoming financial results release and conference call indicates transparency and engagement with investors, fostering trust in the company.
- The Ceribell System's FDA 510(k) clearance highlights the company's commitment to compliance and safety in medical technology.
- Utilization of AI-powered algorithms in the Ceribell System suggests innovation and advanced technology in healthcare diagnostics.
Potential Negatives
- Failure to disclose specific financial expectations or guidance for the upcoming quarter, potentially leaving investors uncertain about future performance.
- Scheduling the financial results release for the same day as the conference call may limit investors' ability to fully digest the information before discussing it.
- Dependent on a potentially high-stress acute care market, which may raise concerns about long-term viability and revenue stability.
FAQ
When will Ceribell release its Q3 2025 financial results?
Ceribell will release its Q3 2025 financial results on November 4, 2025, after market close.
How can I listen to Ceribell's conference call?
Investors can listen to the conference call by calling (800) 715-9871 for domestic or (646) 307-1963 for international participants.
What time is the Ceribell conference call scheduled?
The Ceribell conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.
Where can I find the webcast of the Ceribell conference call?
A live and archived webcast will be available in the "Investor Relations" section of the Ceribell website.
What is the focus of Ceribell, Inc.?
Ceribell is focused on transforming the diagnosis and management of patients with serious neurological conditions using innovative technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBLL Insider Trading Activity
$CBLL insiders have traded $CBLL stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CBLL stock by insiders over the last 6 months:
- XINGJUAN CHAO (President and CEO) has made 0 purchases and 5 sales selling 90,928 shares for an estimated $1,532,157.
- REBECCA B ROBERTSON has made 0 purchases and 4 sales selling 39,460 shares for an estimated $683,155.
- RAYMOND WOO (Chief Technology Officer) has made 0 purchases and 2 sales selling 22,224 shares for an estimated $273,910.
- JOSEPH MICHAEL TAYLOR sold 7,032 shares for an estimated $82,696
- DAVID FOEHR (Senior VP, Finance and PAO) sold 866 shares for an estimated $10,140
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBLL Analyst Ratings
Wall Street analysts have issued reports on $CBLL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Strong Buy" rating on 10/21/2025
To track analyst ratings and price targets for $CBLL, check out Quiver Quantitative's $CBLL forecast page.
Full Release
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/ .
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit
www.ceribell.com
or follow the company on
LinkedIn
.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
[email protected]
Media Contact
Brian Price
[email protected]
